BRISTOL-MYERS SQUIBB COMPANY Postemployment Benefits, Period Expense
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Postemployment Benefits, Period Expense of -$8.00 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PostemploymentBenefitsPeriodExpense · last filed 2014-02-14
- BRISTOL-MYERS SQUIBB COMPANY postemployment benefits, period expense for fiscal 2013 was -$8.00M, a 147.06% decline from fiscal 2012.
- BRISTOL-MYERS SQUIBB COMPANY postemployment benefits, period expense for fiscal 2012 was $17.00M, a 5.56% decline from fiscal 2011.
- BRISTOL-MYERS SQUIBB COMPANY postemployment benefits, period expense for fiscal 2011 was $18.00M, a 0.00% change from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY postemployment benefits, period expense for fiscal 2010 was $18.00M, a 14.29% decline from fiscal 2009.
| Period end | Postemployment Benefits, Period Expense 12 month |
|---|---|
| 2013-12-31 | -$8.00M 10-K · filed 2014-02-14 |
| 2012-12-31 | $17.00M 10-K · filed 2014-02-14 |
| 2011-12-31 | $18.00M 10-K · filed 2014-02-14 |
| 2010-12-31 | $18.00M 10-K · filed 2013-02-15 |
| 2009-12-31 | $21.00M 10-K · filed 2012-02-17 |
| 2008-12-31 | $26.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |